Angiotensin II for Liver Cirrhosis

(Ang2 Trial)

This trial tests a medication called Angiotensin II (brand name Giapreza) to determine if it can more effectively raise blood pressure in people with liver disease experiencing a dangerous drop in blood pressure. Researchers aim to discover whether Angiotensin II can enhance heart and blood vessel function compared to usual treatments. Participants will either receive Angiotensin II or continue with standard care. This trial may suit individuals with liver cirrhosis experiencing septic shock (a severe infection causing dangerously low blood pressure) who have stable heart function and are not on specific other medications. As an Early Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking medical knowledge.

The trial requires that you are not on other vasoactive medications like phenylephrine, Terlipressin, epinephrine, dobutamine, or dopamine. If you are taking any of these, you would need to stop them to participate.

Previous studies have raised safety concerns about Angiotensin II, also known as Giapreza. Research shows that patients receiving this treatment experienced more blood clots than those who did not, with clots occurring more frequently in both arteries and veins among Giapreza-treated patients.

A study involving 321 adults with severe shock also tested Giapreza's safety. While these studies provide some reassurance, they highlight limited information on rare side effects. Although some patients tolerated it well, uncommon side effects might have gone unnoticed due to the small number of participants.

Most treatments for liver cirrhosis focus on managing symptoms and complications, often using vasopressors like norepinephrine to maintain blood pressure. However, Giapreza is unique because it harnesses the power of angiotensin II, a hormone naturally involved in blood pressure regulation, to offer a more direct mechanism of action. This approach could potentially provide more precise control over blood pressure in patients with cirrhosis, making it a promising alternative to traditional vasopressors. Researchers are excited about Giapreza because it might lead to better outcomes for patients by targeting a different aspect of the body's blood pressure regulation system.

Research has shown that Angiotensin II, also known as Giapreza, can effectively raise blood pressure in patients. One study demonstrated that it helped normalize blood pressure in 15 out of 21 people. Angiotensin II is particularly useful for quickly stabilizing blood pressure, with some patients reaching their target levels in just five minutes. It may also improve survival rates, especially when administered early. In this trial, participants will receive either Angiotensin II or standard care treatments to evaluate its effectiveness for liver disease patients with low blood pressure. While more information is still being gathered, these findings suggest that Angiotensin II could be a helpful treatment option.³⁴⁶⁷⁸